Unknown

Dataset Information

0

Polymorphic Region-Specific Antibody for Evaluation of Affinity-Associated Profile of Chimeric Antigen Receptor.


ABSTRACT: Antibody applications in cancer immunotherapy involve diverse strategies, some of which redirect T cell-mediated immunity via engineered antibodies. Affinity is a trait that is crucial for these strategies, as optimal affinity reduces unwanted side effects while retaining therapeutic function. Antibody-antigen pairs possessing a broad affinity range are required to define optimal affinity and to investigate the affinity-associated functional profiles of T cell-engaging strategies such as bispecific antibodies and chimeric antigen receptor-engineered T cells. Here, we demonstrate the unique binding characteristic of the developed antibody clone MVR, which exhibits robust binding to B-lymphoid cell lines. Intriguingly, MVR specifically recognizes the highly polymorphic human leukocyte antigen (HLA)-DR complex and exhibits varying affinities that are dependent upon the HLA-DRB1 allele type. Remarkably, MVR binds to the conformational epitope that consists of two hypervariable regions. As an application of MVR, we demonstrate an MVR-engineered chimeric antigen receptor (CAR) that elicits affinity-dependent function in response to a panel of target cell lines that express different HLA-DRB1 alleles. This tool evaluates the effect of affinity on cytotoxic killing, polyfunctionality, and activation-induced cell death of CAR-engineered T cells. Collectively, MVR exhibits huge potential for the evaluation of the affinity-associated profile of T cells that are redirected by engineered antibodies.

SUBMITTER: Han C 

PROVIDER: S-EPMC7191539 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Polymorphic Region-Specific Antibody for Evaluation of Affinity-Associated Profile of Chimeric Antigen Receptor.

Han Chungyong C   Choi Beom K BK   Kim Seon-Hee SH   Sim Su-Jung SJ   Han Seongeun S   Park Bomi B   Tsuchiya Yohei Y   Takahashi Masaki M   Kim Young H YH   Eom Hyeon-Seok HS   Kitaguchi Tetsuya T   Ueda Hiroshi H   Kwon Byoung S BS  

Molecular therapy oncolytics 20200414


Antibody applications in cancer immunotherapy involve diverse strategies, some of which redirect T cell-mediated immunity via engineered antibodies. Affinity is a trait that is crucial for these strategies, as optimal affinity reduces unwanted side effects while retaining therapeutic function. Antibody-antigen pairs possessing a broad affinity range are required to define optimal affinity and to investigate the affinity-associated functional profiles of T cell-engaging strategies such as bispeci  ...[more]

Similar Datasets

| S-EPMC5904357 | biostudies-literature
| S-EPMC10243493 | biostudies-literature
| S-EPMC8106904 | biostudies-literature
| S-EPMC3804130 | biostudies-literature
| S-EPMC3585808 | biostudies-literature
| S-EPMC5363190 | biostudies-literature
| S-EPMC10378049 | biostudies-literature
| S-EPMC11303627 | biostudies-literature
| S-EPMC6520494 | biostudies-literature
| S-EPMC7433347 | biostudies-literature